“Progress in HIV-1 Vaccine Development”. Washington DC, 1995.
, “Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults”, Vaccine, vol. 29, pp. 5666-5674, 2011.
, “DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial”, PLoS One, vol. 10, p. e0125914, 2015.
, “Effect of Different Vaccination Schedules on Excretion of Oral Poliovirus Vaccine Strains”, J Infect Dis, vol. 192, pp. 2092-2098, 2005.
, “Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults”, J Infec Dis, vol. 197, pp. 667-675, 2008.
, “Evaluation of a Single Dose of Half Strength Inactivated Influenza Vaccine in Healthy Adults”, Vaccine, vol. 20, pp. 1099-1105, 2002.
, “Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults”, J Infec Dis, vol. 177, pp. 1230-46, 1998.
, “Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.”, J Infect Dis, vol. 177, no. 5, pp. 1230-46, 1998.
, “A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.”, AIDS Res Hum Retroviruses, vol. 16, no. 9, pp. 907-19, 2000.
, “A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection”, AIDS Res HumRetroviruses, vol. 16, pp. 907-19, 2000.
, “Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine”, J Infect Dis, vol. 212, pp. 525-530, 2015.
, “Safety and Immunogenicity of a Subvirion Inactivated Influenza a/H5N1 Vaccine With or Without Aluminum Hydroxide Among Healthy Elderly Adults”, Vaccine, vol. 27, pp. 5091-5095, 2009.
, “Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults”, Vaccine, vol. 28, pp. 6367-6373, 2010.
,